View Cart  

United Therapeutics Wants Answers After FDA Denies Its PAH Drug

A A
United Therapeutics (UT) is hoping to get some answers from an end-of-review meeting on why the FDA rejected its oral treprostinil diethanolamine extended-release tablets for pulmonary arterial hypertension (PAH).

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00